-
1Academic Journal
Συγγραφείς: Petkau, V. V., Breder, V. V., Bessonova, E. N., Laktionov, K. K., Stilidi, I. S., Петкау, В. В., Бредер, В. В., Бессонова, Е. Н., Лактионов, К. К., Стилиди, И. С.
Θεματικοί όροι: HEPATOCELLULAR CARCINOMA (HCC), LIVER CANCER, COVID-19, CORONAVIRUS, TARGETED THERAPY, TRANSARTERIAL CHEMOEMBOLIZATION (TACE), ГЕПАТОЦЕЛЛЮЛЯРНЫЙ РАК (ГЦР), РАК ПЕЧЕНИ, КОРОНАВИРУС, ТАРГЕТНАЯ ТЕРАПИЯ, ТРАНСАРТЕРИАЛЬНАЯ ХИМИОЭМБОЛИЗАЦИЯ (ТАХЭ)
Περιγραφή αρχείου: application/pdf
Relation: Scopus; http://elib.usma.ru/handle/usma/7166
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/7166
-
2Academic Journal
Συγγραφείς: V. V. Breder, M. U. Pitkevich, E. R. Virshke, L. A. Kostyakova, I. A. Dzhanyan, K. K. Laktionov, В. В. Бредер, М. Ю. Питкевич, Э. Р. Виршке, Л. А. Костякова, И. А. Джанян, К. К. Лактионов
Πηγή: Meditsinskiy sovet = Medical Council; № 10 (2018); 27-32 ; Медицинский Совет; № 10 (2018); 27-32 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-10
Θεματικοί όροι: BCLC, HCC, transarterial chemoembolization (TACE), sorafenib, regorafenib, ГЦР, трансартериальная химиоэмболизация (ТАХЭ), сорафениб, регорафениб
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2529/2497; Siegel R et al. Cancer statistics, 2014. CA. Cancer J Clin, 2014. 64(1): 9–29.; Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 году. Известия Тинро, 2014. 226: 1-226.; Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2013 году. ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. 235 с.; Bruix J et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 2001, 35(3): 421–430.; Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg, 1964, 1: 1–85.; Uehara T et al. Molecular mechanisms of fibrosis-associated promotion of liver carcinogenesis. Toxicological sciences, 2013, 132(1): 53–63.; Бредер В.В. Стратегия и тактика консервативного лечения гепатоцеллюлярного рака, 2017.; Di Costanzo GG, Tortora R, Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol, 2015 May 28, 7(9): 1184-1191.; EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma J Hepatol, 2018. Doi:10.1016/j.jhep.2018.03.019.; Виршке Э.Р., Косырев В.Ю., Долгушин Б.И. Гепатоцеллюлярный рак, BCLC-B: в поисках оптимального лечения. Интервенционные радиологические технологии в лечении больных ГЦР. Злокачественные опухоли, 2016, 4(спецвып. 1): 26–28.; Huppert P. Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdom Imaging, 2011, 36(6): 677-683.; Aerts M et al. Current status and perspectives of immune-based therapies forhepatocellular carcinoma. World J Gastroenterol, 2016, 22(1): 253–261.; Ali MY et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol Elsevier, 2005, 43(5): 817–822.; Zerbini A et al. Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance TumorSpecific T-Cell Responses. Cancer Res, 2006, 66(2).; Bolondi L et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions Semin Liver Dis, 2012, 32(4): 348–359.; Llovet JM et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002, 359(9319): 1734-9.; Terzi E et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed on demand. J Hepatol, 2012, 57(6): 1258-67.; Sieghart W et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology, 2013, 57: 2261–2273.; Kadalayil L et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol, 2013, 24(10): 2565–2570.; Hucke F et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol, 2014, 61(6): 1287-1296.; Arizumi T et al. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer, 2015 Dec, 4(4): 253–262.; Kudo M et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the liver cancer study group of Japan. Liver Cancer, 2014, 3(3–4): 458–468.; Raoul JL et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treatment Reviews, 2011: 212-220.; Colombo M et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med, 1991, 325: 675-680.; Ioannou GN et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol Elsevier, 2007, 5(8): 938–945, 945-4.; Cabibbo G et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol, 2012, 4(9): 256– 261.; Leung TWT et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res, 1999, 5(7): 1676– 1681.; Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390.; Cheng A-L et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol Elsevier, 2009, 10(1): 25–3.; Iavarone M et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology, 2011, 54(6): 2055-63.; Ganten TM et al. Sorafenib in patients with hepatocellular carcinoma – results of the observational INSIGHT study. Clin Cancer Res, 2017, 23(19): 5720–5728.; Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Investig Drugs, 2012, 21(6): 879–889.; Bruix J et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2016, 0(0): 1020–1022.; Finn RS et al. Proc ASCO GI. San Francisco, USA, 19–21 Jan 2017, abstract 344.; Lencioni R. Chemoembolization in Patients with Hepatocellular Carcinoma. Liver Cancer, 2012, 1(1): 41–50.; Meyer T et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol, 2017, 2: 565–75.; Kudo M et al. Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. J Clin Oncol, 2018, 36(suppl, abstr 4017).